A pharma CEO just found out the captain doesn’t always go down with the ship. Sometimes the ship stays afloat by handing him to DOJ.

Veloxis Pharmaceuticals just paid over $46 million to resolve a kickback scheme involving its kidney transplant drug, lavish meals, resort stays, payments dressed up as consulting fees paid to doctors and pharmacies to drive prescription demand.

Here’s the part that should stop you.

The deferred prosecution agreement says the company’s own former CEO was directing this.

That’s the kind of fact pattern that usually gets a company prosecuted, not offered a deal, but Veloxis got a deferred prosecution agreement anyway under DOJ’s corporate enforcement policy.

Why?

Because after the conduct came to light, the company disclosed, cooperated, and identified and fired the people responsible, including its own CEO.

The lesson is clear.

Even executive-level misconduct doesn’t actually doom the corporate entity if your response afterward is real.

Disclosure, cooperation, and actually removing the people responsible is exactly the formula DOJ rewards.

Don’t assume C-suite involvement means game over. What you do next is what actually decides the outcome.

The Ethics and Compliance Q and A show is produced by One Stone Creative.